Drug Shortage Report for SANDOZ RIVASTIGMINE PATCH 5
Report ID | 221841 |
Drug Identification Number | 02426293 |
Brand name | SANDOZ RIVASTIGMINE PATCH 5 |
Common or Proper name | RIVASTIGMINE PATCH 5 |
Company Name | SANDOZ CANADA INCORPORATED |
Market Status | MARKETED |
Active Ingredient(s) | RIVASTIGMINE |
Strength(s) | 4.6MG |
Dosage form(s) | PATCH |
Route of administration | TRANSDERMAL TRANSDERMAL |
Packaging size | 30 TTSM |
ATC code | N06DA |
ATC description | ANTI-DEMENTIA DRUGS |
Reason for shortage | Disruption of the manufacture of the drug. |
Anticipated start date | |
Actual start date | 2024-03-11 |
Estimated end date | 2024-04-12 |
Actual end date | 2024-04-15 |
Shortage status | Resolved |
Updated date | 2024-04-16 |
Company comments | |
Health Canada comments | |
Tier 3 Status | No |
Contact Address | 110 RUE DE LAUZON BOUCHERVILLE, QUEBEC CANADA J4B 1E6 |
Company contact information | 1 800-361-3062 |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
Version Number | Date Updated | Language | |
---|---|---|---|
v7 | 2024-04-16 | French | Compare |
v6 | 2024-04-16 | English | Compare |
v5 | 2024-04-08 | French | Compare |
v4 | 2024-04-08 | English | Compare |
v3 | 2024-03-12 | English | Compare |
v2 | 2024-03-11 | French | Compare |
v1 | 2024-03-11 | English | Compare |
Showing 1 to 7 of 7